Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9427165 | 0.87 | MEN1 (0.51) | DRD4MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL24137898 | 0.85 | MEN1 (0.62) | DRD4MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL52143 | 0.85 | MEN1 (0.62) | DRD4MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL2077308 | 0.85 | MEN1 (0.62) | DRD4MEN1KMT2ASLC6A2SLC6A4 | |
| Ammonia Solution, Strong SCHEMBL28002354 | 0.83 | MEN1 (0.61) | DRD4MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL8485 | 0.81 | SLC6A2 (0.42) | DRD4SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL26095542 | 0.81 | DRD4 (0.58) | DRD4MEN1KMT2ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL12503316 | 0.80 | KDM4E (0.41) | DRD4SLC6A2SLC6A4SLC6A3TAAR1 | |
| Ammonia Solution, Strong SCHEMBL27469603 | 0.80 | SLC6A2 (0.41) | DRD4SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL20184270 | 0.77 | USP2 (0.40) | DRD4MEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263142-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | CAN-FITE BIOPHARMA LTD. (IL) | 2016-09-15 | — | — | US | claimed |
| US-9387220-B2 | Method for inducing hepatocyte proliferation and uses thereof | CAN-FITE BIOPHARMA LTD. (IL) | 2016-07-12 | — | — | US | claimed |
| EP-1945211-B1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | claimed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-20140364388-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN-FITE BIOPHARMA LTD. (IL) | 2014-12-11 | — | — | US | claimed |
| US-8846635-B2 | Method for inducing hepatocyte proliferation and uses thereof | CAN-FITE BIOPHARMA LTD. (IL) | 2014-09-30 | — | — | US | claimed |
| EP-2227234-B1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN FITE BIOPHARMA LTD (IL) | 2014-05-07 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | The united States of America,as represented by Secretary,Dept.,of Health and Human Services (US) | 2013-05-02 | — | — | US | claimed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | claimed |
| EP-0556310-B1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER (US) | 1995-07-05 | — | — | EP | claimed |
| EP-0613477-A1 | TRIAZINE DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER INC. (US) | 1994-09-07 | — | — | EP | claimed |
| EP-0556310-A1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY. | PFIZER (US) | 1993-08-25 | — | — | EP | claimed |
| WO-1993010116-A1 | TRIAZINE DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER INC. (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0220735-B1 | 3(2H)-PYRIDAZINONE DERIVATIVES, A PROCESS AND INTERMEDIATES FOR PREPARING THEM AND MEDICAMENTS CONTAINING THEM AND/OR OTHER 3(2H)-PYRIDAZINONE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1993-05-19 | — | — | EP | claimed |
| CN-1061411-A | Be used to strengthen the active quinazoline derivant of antineoplastic agent | PFIZER (US) | 1992-05-27 | — | — | CN | claimed |
| WO-1992007844-A1 | QUINAZOLINES DERIVATIVES FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER INC. (US) | 1992-05-14 | — | — | WO | claimed |
| US-4826845-A | HYPOTENSIVE, ADRENERGIC BLOCKING AGENTS | RICHTER GEDEON VEGYESZETI GYAR T.R. (HU) | 1989-05-02 | — | — | US | claimed |
| EP-0220735-A2 | 3(2H)-pyridazinone derivatives, a process and intermediates for preparing them and medicaments containing them and/or other 3(2H)-pyridazinone derivatives | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1987-05-06 | — | — | EP | claimed |
| US-4349549-A | Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s | SYNTEX (U.S.A.) INC. (US) | 1982-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364388-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | HGF, HCAR3, HNF4A | DRD4 2505/4885MEN1 4262/4885KMT2A 2651/4885 |
| US-20160263142-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | ADORA3, ADORA2A, ADORA1 | DRD4 1735/4885MEN1 2844/4885KMT2A 2622/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | DRD4 792/4885MEN1 1394/4885KMT2A 2403/4885 |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | NT5E, NT5C2, NT5C3B | DRD4 3280/4885MEN1 1736/4885KMT2A 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.